Market commentary points to booming GLP-1 demand, while Eli Lilly remains a baseline benchmark
A recent market-news post argues that GLP-1 growth is driving demand beyond the usual duopoly of Eli Lilly and Novo Nordisk, spotlighting two other companies as potential beneficiaries.